source
- Sellas vaccine shows 9-month overall survival gain in phase 3 AML trialSellas Life Sciences reported results of a phase 3 trial of its peptide vaccine galinpepimut-S (GPS) in patients with acute myeloid leukemia (AML). The study met its primary endpoint, showing a me…
- FDA rejects Summit Therapeutics' ivonescimab combo, citing lack of survival benefit in lung cancerSummit Therapeutics and partner Akeso received a rejection from the U.S. Food and Drug Administration for their PD-1/VEGF antibody ivonescimab combined with chemotherapy. The agency said the data d…